tradingkey.logo
搜尋

Avalyn Pharma Ord Shs (Proposed)

AVLN
添加自選
30.280USD
-0.310-1.01%
收盤 11-13 16:00(美東)
1.34B總市值
0.00本益比TTM

關於 Avalyn Pharma Ord Shs (Proposed) 公司

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Avalyn Pharma Ord Shs (Proposed) 簡介

公司代碼- -
公司名稱- -
上市日期- -
CEO- -
員工數量- -
證券類型- -
年結日- -
公司地址- -
城市- -
上市交易所- -
國家- -
郵編- -
電話- -
網址- -
公司代碼- -
上市日期- -
CEO- -

Avalyn Pharma Ord Shs (Proposed)公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Erin M. Lavelle
Ms. Erin M. Lavelle
Independent Director
Independent Director
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Dr. Robert Meyer, M.D.
Dr. Robert Meyer, M.D.
Independent Director
Independent Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Director
Independent Director
--
--
Mr. Jon Congleton
Mr. Jon Congleton
Independent Director
Independent Director
--
--
Dr. David Friedman, M.D.
Dr. David Friedman, M.D.
Independent Director
Independent Director
--
--
Dr. Melissa Rhodes, Ph.D.
Dr. Melissa Rhodes, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Erin M. Lavelle
Ms. Erin M. Lavelle
Independent Director
Independent Director
--
--
Mr. Douglas (Doug) Carlson
Mr. Douglas (Doug) Carlson
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Lyn Baranowski
Ms. Lyn Baranowski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Ketan Patel, M.D.
Dr. Ketan Patel, M.D.
Independent Director
Independent Director
--
--
Dr. Robert Meyer, M.D.
Dr. Robert Meyer, M.D.
Independent Director
Independent Director
--
--

常見問題

Avalyn Pharma Ord Shs (Proposed)的前五大股東是誰?

Avalyn Pharma Ord Shs (Proposed)的前五大股東如下:Dr. Ketan Patel, M.D.
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有